Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials... The post Inside Precision Medicine: Asked & Answered with Artiva’s CMO Dr. Subhashis Banerjee appeared firs...| Artiva Biotherapeutics
In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more... The post Pharmaceutical Manufacturer Q&A: Arti...| Artiva Biotherapeutics
In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and... The post GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge appeared first on Artiva Biotherapeutics.| Artiva Biotherapeutics
NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t... The post The Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease appeared first on Artiva Biotherapeutics.| Artiva Biotherapeutics
Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo. In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Read the full article here (subscription may be required). The post In Vivo: Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm appeared first on Artiva Biotherapeutics.| Artiva Biotherapeutics
DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer,... The post Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions appeared first on Artiva Biotherapeut...| Artiva Biotherapeutics
Natural killer cells continuously patrol the human body, swiftly eliminating viruses and cancer cells, like sharks in prey-laden waters. Several biotech companies are harnessing the power of these innate immune crusaders in oncology and autoimmune diseases, potentially positioning them as a strong competitor to CAR-T cell therapies. “The advantage of NK cells over a T-cell approach... The post PharmaVoice: Natural Killer Cells, a Rising Alternative to CAR-T Cell Therapy appeared first on A...| Artiva Biotherapeutics
Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’... The post Cell & Gene The Podcast: The Future of NK Cell Therapy for Autoimmune Disease appeared first on Artiva Biotherapeutics.| Artiva Biotherapeutics
Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots discusses: Immune reset in oncology has been observed with approved autologous CAR-T products. A study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Artiva’s AlloNK, an allogeneic,... The post PharmaShots: Enhancing Care with NK Cell Therapy appeared first o...| Artiva Biotherapeutics
Chris Horan, Artiva’s Chief Technical Operations Officer, talks with BioProcess Insider about why decreased risk and inexpensive manufacturing might give allogeneic natural killer (NK) cell therapies the edge over chimeric antigen receptors (CAR)-T therapies. Read the article here. The post BioProcess Insider: Artiva Discusses Scalable NK Cells to Treat Autoimmune Diseases appeared first on Artiva Biotherapeutics.| Artiva Biotherapeutics
AlloNK is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of mAbs to drive B-cell depletion.| Artiva Biotherapeutics